Share Name Share Symbol Market Type Share ISIN Share Description
Proteome LSE:PRM London Ordinary Share GB0003104196 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 4.82p 4.66p 5.05p - - - 93,734.00 11:56:21
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 1.9 -3.3 -1.2 - 14.19

Proteome Share Discussion Threads

Showing 173901 to 173920 of 173925 messages
Chat Pages: 6957  6956  6955  6954  6953  6952  6951  6950  6949  6948  6947  6946  Older
DateSubjectAuthorDiscuss
21/2/2017
10:57
muttlly 20 Feb '17 - 16:58 - 68577 of 68579 12 0
avatar333
21/2/2017
06:10
From today's Guardian: "The prospect of an effective treatment for Alzheimer’s has had knockbacks in the past year as a string of drugs designed to sweep away the amyloid plaques seen in the brains of patients have each been shown to make no difference to the rate of cognitive decline in trials. Between 2002 and 2012, 99.6% of drugs studies aimed at preventing, curing or improving Alzheimer’s symptoms were either halted or discontinued."
small crow
20/2/2017
18:52
Capitulation .... at a price twice that of today's.
alchemy
20/2/2017
16:58
This new poster comes across as a complete KOCK!!!! saul goodman 20 Feb '17 - 14:49 - 68576 of 68576 0 0 (Filtered) =====================================================================================
muttlly
20/2/2017
14:04
http://www.bbc.co.uk/news/uk-england-manchester-39020384 Hmmm! Not sure about the reputational damage to Randox.
jeffian
20/2/2017
12:45
I note that the word "may" is used twice in the final sentence of the conclusion.
jeffian
20/2/2017
11:40
Identification of candidate cerebrospinal fluid biomarkers in parkinsonism using quantitative proteomics. Ian Pike Malcolm Ward Proteome Sciences, London,UK and Authors at :- Department of Molecular Neuroscience, UCL Institute of Neurology, Queen Square, London, UK. Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden Abstract INTRODUCTION: Neurodegenerative parkinsonian syndromes have significant clinical and pathological overlap, making early diagnosis difficult. Cerebrospinal fluid (CSF) biomarkers may aid the differentiation of these disorders, but other than α-synuclein and neurofilament light chain protein, which have limited diagnostic power, specific protein biomarkers remain elusive. CONCLUSION: Using an unbiased proteomic approach, proteins were identified that were able to differentiate atypical parkinsonian syndrome patients from healthy controls. Our study indicates that markers that may reflect neuronal function and/or plasticity, such as the amyloid precursor protein, and inflammatory markers may hold future promise as candidate biomarkers in parkinsonism. HTTPS://www.ncbi.nlm.nih.gov/pubmed/?term=28214264
colinhy
18/2/2017
11:30
Stocky......This is exactly the reason why you make things so difficult for yourself and the many others who are so reluctant to communicate with you. Read my post again......I asked for your opinion whether to buy now, or wait until later if you thought that the share price may be lower.Straight away you accuse me of "attacking" the stock and start banging on about how much that you think I am upset about losing money, even after having told you, now, at least 3 times in the recent past that I printed a 95pps profit on 350k PRM shares back in 2004.Now we know that the chances of that ever happening again are absolutely zero, but for alky and a few of the chaps who are looking to have a little flutter, and may well value your opinion, would you buy now or wait to see if the share price will go lower?
badger60
18/2/2017
10:02
bodger, you are incredibly obsessive about attacking this stock for someone claiming not to have lost money on it what a pair you and fgnoms are. He at least admits holding 1m shares and losing a fortune
stocktastic
18/2/2017
09:14
Thermo Fisher Webinar March 16, 2017 Open 10 Doors at Once: Sample Multiplexing with 10-plex Tandem Mass Tags (TMT) Provides a New Perspective on any Biology. The ability to perform accurate protein quantification at low levels lets scientists unravel the complexity of protein interactions, and track protein abundance changes in a wide variety of samples and applications. The proteome is complex and dynamic and innovative tools are needed to study the complexities of biology. In fact, the full measure of proteome changes can rarely be encapsulated in a single time point representing a snapshot of the dynamics. Sample multiplexing using Tandem Mass Tag (TMT) when combined with an appropriate Thermo Scientific Orbitrap HRAM MS enables scientists to ask real questions of their samples and obtain a meaningful description of how protein expression changes with disease, with the progression of time, and even within different parts of the cell. TMT workflows enable more than simple multiplexed quantitation; they open the door to defining whole new sets of questions. In this webinar, case studies will be highlighted from the Gygi lab and ThermoFisher Center for Multiplexed Proteomics at HMS demonstrating the robustness of the technique, and more importantly, how to apply these workflows to a variety of analyses to answer a breadth of biological questions. HTTP://cen.acs.org/media/webinar/thermo_031617.html
colinhy
18/2/2017
03:40
You're asking an ex Meldex shareholder ("it was fraud" bawl bawl) for investment advice Badger? The guy is the worst sufferer of Murphy's Syndrome that I've ever known. Whatever he says do the opposite.
jamtomorrow2
18/2/2017
03:16
Having said all that stocky, are you saying that it would be better to buy shares now or wait until the price drops a bit?
badger60
17/2/2017
16:18
jeffian I think it's important to differentiate 'continued search for markers and drug testing' - PRM has been gradually moving away from internal and grand projects here 'continued search for markers and drug testing' - Externally, as in trying to make money off firms working on this, yes, very much so Re 'if continued, would appear to get them through (just) without another fundraising and I think it becomes another story once the company becomes self-sustaining financially' I'm quite surprised to hear this from you, but yes, that is the strategy and I also agree it is not an unrealistic prospect The less intelligent folk here will just blindly attack the company without actually stopping to think about things in the way you have!
stocktastic
17/2/2017
11:15
Just to give everyone a laugh, I have to tell you that I have seriously considered taking a punt. Only 'fruit machine' money, but it may be worth a gamble if I'm prepared to risk losing my stake. The apparent acceleration in H2 revenues (pace badger/jam's(?) claim it was all currency related), if continued, would appear to get them through (just) without another fundraising and I think it becomes another story once the company becomes self-sustaining financially. I'm not sure about 'profitability in 2018' (I think there is still a lot of confusion between revenues and profit!), but just assured survival changes the ball game. Alchemy's 'capitulation' was another contra-cyclical indicator! 8-) Some years's ago, although not a holder, I attacked the business model of Regus, the serviced office provider since renamed IWG, and was sure it was going to go bust. To all intents and purposes it did, going down from £4 to around 3p with one large institutional holder capitulating and selling out at 1.8p, but remarkably - and after some 'interesting' shenanigans involving John Mouton's Better Capital group - it survived. Price today? 265p. Spotting spotty dog's is one thing. Spotting the moment they change their spots can bring rewards.
jeffian
17/2/2017
10:54
That's not "yes and no", it's "yes" isn't it, doc? We're saying exactly the same thing. Whilst the Holy Grail of a certain diagnosis and/or a blockbuster drug is some way off, the continued search for markers and drug trials mean that that side of PRM's business is secured and growing.
jeffian
17/2/2017
10:20
jeffian "The continued search for markers and drug testing is presumably what Haigh's strategy is all about when he says he wants to make TMT and pharma services the 'core business' of PRM" Yes and no. Haigh's strategy is about things like a) focusing on facilitating more growth of the TMT royalty stream ie. working with Thermo to broaden its use into the mainstream, via greater awareness of existing workflows and introduction of new chemistry types b) selling PRM's contract service business to clients, to get more repeat business, larger contract sizes and work with new clients PRM has in the past invested a lot in AD marker panels with KCL Clearly some of a and b could relate to AD projects, just as much as anything else, but I'd separate what Haigh is trying to do from any of PRM's past AD efforts. Whether there's anything still to be had from the AD panels or ongoing work, I don't know. I'd guess that they'll probably just be advanced slowly by grants etc. rather than be a focus of any of PRM's investment
stocktastic
17/2/2017
09:38
Good luck alky. I see 90k has traded today. Hopefully you will be able to knock those out sometime soon in the mid 5's and make yourself a few bob.
badger60
17/2/2017
08:17
Surely Al's post deserves to be included in JT's above list of amusing posts. There's been precious little humour or significant or informative posts included over recent times.
jamtomorrow2
17/2/2017
07:53
May I echo teh avatar 'saul goodman's' good wishes to teh avatar Alchemy in teh event that he chooses teh course of action currently under consideration.
monte1
17/2/2017
07:31
Wow! Well, good luck if you do, Al.
saul goodman
Chat Pages: 6957  6956  6955  6954  6953  6952  6951  6950  6949  6948  6947  6946  Older
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:40 V: D:20170221 12:11:26